Post di Arrow Diagnostics

Uncovering the Genetic Landscape of Breast Cancer with Circulating Tumour Cells (CTCs) 🔍 Breast cancer, the leading cause of cancer-related deaths in women, is particularly challenging to treat due to evolving PIK3CA gene mutations, which contribute to resistance against chemotherapy and hormone therapy. 💡 Our recommended read this month explores how circulating tumour cells (CTCs) released by tumours into the bloodstream, can serve as a "real-time biopsy," offering a more accurate representation of the tumour’s current genetic state compared to traditional methods. 🔬 At 4bases , we leverage the power of Next Generation Sequencing (NGS) technology with our Pancancer Pro oncological kit allowing for the somatic analysis of 95 genes related to various solid tumours. 👉 Click here: https://lnkd.in/dC2RmjMc to read more! #BreastCancer #PrecisionMedicine #NGS #HealthcareInnovation

🧬 Why should you consider a matched tumor-normal approach for your genomic profiling? One major limitation of tumor-only sequencing is its inability to accurately distinguish somatic mutations driving tumorigenesis from germline and clonal hematopoietic variants. Having a complete picture of a tumor’s genomic makeup is crucial for accurate assessment and informed decision-making. In our latest blog, we discuss the benefits of matched tumor-normal sequencing, including its ability to: ➡️ Retain true somatic variants calls. ➡️ Reduce noise caused by sample variability and sequencing artifacts. ➡️ Remove false positives originating from clonal hematopoietic of indeterminate potential (CHIP) variants. ➡️ Streamline germline variant analysis. Read here to learn more: https://loom.ly/WV8JOF0 #NGS #Oncology #CGP #LiquidBiopsy #SolidTumors

📣 New offering alert! We're thrilled to announce OncoPortal™ Mutation Tracker— a longitudinal #MRD tracking tool designed for disease monitoring in the context of oncology. This innovation underscores our commitment to advancing data-driven approaches for improved oncology insights. The OncoPortal™ Mutation Tracker augments the SOPHiA DDM™ Platform’s core analytical capabilities to allow clinical researchers to longitudinally monitor evolving genomic variants across multiple time points, providing a comprehensive view of disease evolution. “The ability to reliably track low frequency variants longitudinally is a game-changer because it allows the detection of even the smallest traces of cancer that can evade traditional methods of testing and ultimately drive relapse. With this new longitudinal tracking capability, we offer a highly customizable, user-friendly solution to enable the generation of novel insights for clinical research. Precise tracking of key genomic variants over time has the potential to eventually enable earlier intervention and more tailored disease management, which may lead to better long-term outcomes for patients.” said Philippe Menu, M.D., Ph.D., Chief Medical Officer and Chief Product Officer. Learn more about our offering here: https://lnkd.in/evnuPsyh #DataDrivenMedicine #OncoPortal #Oncology #Cancer

💡 Revolutionary Mitochondrial Transfer Boosts T Cell Fitness and Antitumor Efficacy💡 👏 Congratulations to Jeremy Baldwin from the group of Luca Gattinoni and Shiladitya Sengupta for their groundbreaking work on intercellular mitochondrial transfer, enhancing T cell metabolic fitness and antitumor efficacy. 🔍 This study introduces a novel platform that leverages bone marrow stromal cells to transfer healthy #mitochondria to CD8+ T cells, overcoming T cell exhaustion—one of the biggest barriers in #immunotherapy for #cancer. By enhancing mitochondrial respiration and resistance to exhaustion, the team showed that mitochondria-boosted T cells could expand more robustly, infiltrate tumors more efficiently, and deliver superior antitumor responses, ultimately prolonging survival in preclinical models. 💊 The findings are highly relevant to the unmet medical need in cancer immunotherapy, particularly for solid tumors. Current therapies often face challenges with T cell #exhaustion due to a hostile tumor #microenvironment. The introduction of this mitochondrial transfer technology represents a significant advancement in organelle medicine, opening new pathways for more effective cell therapies. 🥼 Luca Gattinoni, with his extensive background in immunotherapy and cellular engineering, has been instrumental in pushing the boundaries of adoptive T cell therapies. 🏛️ This work highlights the importance of multidisciplinary and multinational collaborations, demonstrating how joint efforts across institutions like the The National Institutes of Health, LIT - Leibniz Institute for Immunotherapy, Harvard-MIT Health Sciences and Technology (HST) and institutions like the IRCCS Ospedale San Raffaele, showcasing the critical role of global partnerships in pushing the limits of innovation in cancer treatment. 👏 Kudos to the entire research team: Jeremy G. Baldwin, Christoph Heuser-Loy, Tanmoy Saha, Roland C. Schelker, Dragana Slavkovic Lukic, Nicholas Strieder, Inmaculada Hernandez-Lopez, Nisha Rana , Markus Barden, Fabio Mastrogiovanni, Azucena Martín-Santos, Andrea Raimondi, Philip "Zach" Brohawn, Brandon W. Higgs, Claudia G., Veena Kapoor, William G. Telford, Sanjivan G., Maria Xydia, Philipp Beckhove, Sina Frischholz, Kilian Schober, Zacharias Kontarakis, Jacob E. Corn, Matteo Iannacone, Donato Inverso, Michael Rehli, Jessica Fioravanti, Shiladitya Sengupta, and Luca Gattinoni. Read below the full paper ⤵

💡 Read our latest Guidelines Spotlight! This year the ESMO Precision Medicine Working Group updated their recommendations for the use of next-generation sequencing (NGS) in advanced cancer. Reflecting advances in the field of precision oncology, the recommendations were expanded to include advanced #BreastCancer and additional rare tumor types. They also encompass the detection of tumor-agnostic alterations in metastatic cancers where access to matched therapies is available. We offer NGS applications that cover key biomarkers highlighted in the recommendations, including SOPHiA DDM™ Dx Homologous Recombination Deficiency (HRD) Solution, which has been recognized by ESMO as a validated method for HRD detection in advanced ovarian cancer. Read our blog to learn more: https://loom.ly/OPxrPKY #NGS #Oncology #ESMO

Identifying the oncological impact of BRCA1/2 pathogenic variants in males 💡 The recommended read for this month dives into hidden risks for male BRCA1/2 carriers, including elevated risks of prostate, pancreatic, and breast cancers, and learn about the latest in genetic testing and treatments, like PARP inhibitors, that could improve outcomes for these men. 🧬🔬 We at 4bases  harness the power of Next Generation Sequencing in our BraCA panel kit, which allows for the analysis of the BRCA1 and BRCA2 genes for identification of hereditary predisposition. 👉 Click here: https://lnkd.in/dNA2WCGN to read more and to explore how better testing and early detection can make a difference! #NGS #Oncology #HealthcareInnovation

📣 Don't miss our live webinar! Join us next week on September 10th 15:00 CEST / 09:00 EDT for a live interactive webinar with Frontline Genomics! In this webinar, we will demonstrate how to better handle the complexity of NGS data analysis and variant interpretation, to confidently assess genetic variants predisposing to cancer. Attendees will learn more about novel enhanced tools for hereditary cancer research, exploring real-life application examples from two major European Cancer Institutes. 💡What will you learn? - Analytical performance results of a study conducted in collaboration with a UK hospital, based on a set of challenging clinical samples and the implementation of SOPHIA DDM™ Hereditary Cancer Solution (HCS) v2.0, at the European Institute of Oncology. - Explore the guideline-driven content, enhanced features and streamlined workflow of SOPHIA DDM™ Hereditary Cancer Solution (HCS) v2.0. - Discover improved analytical capabilities for detection of copy number variants (CNVs), Alu insertions, Boland insertions and PMS2/PMS2CL gene conversion. Don't miss it! Register here: https://loom.ly/_FIuVzQ #HereditaryCancer #Oncology #CancerResearch #Webinar #DataDrivenMedicine

📣 SOPHiA DDM™ Dx Homologous Recombination Deficiency (HRD) Solution is recognized as a validated #HRD detection method in the latest ESMO recommendations for next-generation sequencing (NGS). Considering the potential benefit of PARPi, ESMO recommends carrying out BRCA1/2 and HRD testing using a validated assay in patients with advanced ovarian cancer. 💡 SOPHiA DDM™ Dx HRD Solution is a CE-IVD marked, decentralized application that leverages low-pass whole genome sequencing data to accurately detect HRD status in ovarian cancer and inform treatment decision-making. Read the full ESMO recommendations here: https://loom.ly/CSz9Vcs Learn more about our deep learning-based approach to HRD assessment here: https://loom.ly/vF3tNOY #NGS #PrecisionMedicine #OvarianCancer

🇬🇧 Webinar alert! Join the online interactive learning session to understand and discuss the recent changes in HRD testing for Ovarian Cancer offered by the North Thames Genomics Laboratory Hub (NTGLH). 💡 What you will learn: • Testing Changes: Detailed explanation of the changes to HRD testing for advanced ovarian cancer implemented across North Thames since December 2023. • Clinical Impact: Insights into what these changes mean for clinicians and their teams, with opportunities for questions and clarifications. • New Reporting System: Overview of the changes to the HRD report and scoring system, including template examples and where to find key information. • Validation and Confidence: Discussion on the validation work done before the test went live, comparison of all 4 assays, and review of clinical data from SOPHiA GENETICS. • Open Discussion: Engage in an open table discussion around all aspects of the new service, addressing specific requirements and differences in the new HRD reports. Why Attend? ↳ NICE Guidelines Compliance: Understand how to comply with NICE guidelines recommending genomic testing for HRD in patients with ovarian, breast, and prostate cancer to identify eligibility for PARP inhibitors treatment. ↳ Enhanced Understanding: Gain a comprehensive understanding of the HRD send-away service and its specific requirements. ↳ Expert Insights: Benefit from the expertise of leading professionals in the field, ask questions, and clarify any doubts regarding the new HRD testing service. 🔗 Register now: https://loom.ly/wa9sUv4 #HRD #Webinar #OvarianCancer #Oncology #NHS NHS North Thames Genomic Medicine Service The Royal Marsden NHS Foundation Trust

🇨🇭Next stop...Basel! ✈️ Meet our team at the 2024 Annual Meeting of the German, Austrian, and Swiss Societies for Hematology and Medical Oncology in Basel from 11-14 October and learn more about our recent developments in Oncology and beyond! 📍Stop by our booth 1.05 and get to experience firsthand our New Generation SOPHiA DDM™ Platform and learn more about our different applications and offerings in oncology, rare diseases, and inherited disorders. We can't wait to meet you! #DGHO #DGHO2024 #oncology #hematology #medicaloncology #precisionmedicine